Butopamine (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; developmental code name LY-131126; also known as (R,R)-ractopamine) is a sympathomimetic agent, β-adrenergic receptor agonist, and positive inotrope of the phenethylamine family which was studied for treatment of heart failure but was never marketed.[1][2][3][4] It is an analogue of dobutamine[3][4] and is the (R,R)-enantiomer of ractopamine.[2] Butopamine is not a catecholamine and is resistant to metabolism by catechol O-methyltransferase (COMT).[3] In contrast to dobutamine, butopamine is orally active.[3] In addition to its positive inotropic effects, butopamine has positive chronotropic effects.[3]

References

  1. ^ Elks J (2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer US. p. 199. ISBN 978-1-4757-2085-3. Retrieved 27 February 2025.
  2. ^ a b Morton IK, Hall JM (2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Netherlands. p. 58. ISBN 978-94-011-4439-1. Retrieved 27 February 2025.
  3. ^ a b c d e Hess HJ (1981). Annual Reports in Medicinal Chemistry. Academic Press. p. 96. ISBN 978-0-08-058360-0. Retrieved 27 February 2025.
  4. ^ a b Chatterjee K (March 1985). "Recent advances in the management of chronic heart failure". Prim Care. 12 (1): 117–142. doi:10.1016/S0095-4543(21)01244-6. PMID 3846305.



Allikas: https://en.wikipedia.org/wiki/Butopamine
No tags for this post.